Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells
- 24 February 2013
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 125 (6) , 891-900
Abstract
Ganglioglioma is a rare CNS tumor with a benign biological behavior. Recently, the BRAF V600E mutation was identified in approximately 20 % of gangliogliomas. Here, we analyzed a total of 71 gangliogliomas for BRAF V600E mutational status by VE1 immunohistochemistry and direct DNA sequencing. The BRAF V600E mutation was detected in 41/71 (58 %) gangliogliomas by immunohistochemistry. DNA sequencing was concordant in 60 of 62 analyzed cases. BRAF status was compared with clinical, histological and immunohistochemical data. Presence of the BRAF V600E mutation was associated with expression of synaptophysin in the tumor (p = 0.0008), presence of dysplastic neurons (p = 0.011) and lymphocytic cuffs (p = 0.018), and with younger age (p = 0.0054). Extensive hemosiderin deposition within the tumor was significantly associated with BRAF wild-type status (p = 0.042). No significant association was found with proliferation (p = 0.053), presence of phospho ERK (p = 0.1) or senescence marker p16INK4a (p = 0.22). Using VE1, we localized the BRAF V600E-mutated protein predominantly to the neuronal compartment, indicating that BRAF mutations occur in cells that have the capacity to differentiate into ganglionic cells. In many cases mutant BRAF is additionally expressed by the glial compartment, indicating that in these cases the cell targeted by BRAF mutation was likely capable of differentiating along both the ganglionic and glial lineages. No cases with an exclusive expression of BRAF V600E in the glial compartment were observed. Thus, using VE1 we identified the neuronal compartment as an essential part of this mixed glioneuronal tumor.Keywords
This publication has 43 references indexed in Scilit:
- Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCRHuman Pathology, 2013
- Detection of BRAF p.V600E Mutations in MelanomasThe Journal of Molecular Diagnostics, 2013
- Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinomaEndocrine-Related Cancer, 2012
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastasesActa Neuropathologica, 2011
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibodyActa Neuropathologica, 2011
- Malignant ganglioglioma: case report and review of literatureJournal of Neuro-Oncology, 2010
- Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in ChildrenJournal of Clinical Oncology, 2007
- Immunogenicity of Constitutively Active V599EBRafCancer Research, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- Mutational analysis of TSC1 and TSC2 genes in gangliogliomasNeuropathology and Applied Neurobiology, 2001